Dogwood Therapeutics — Third Quarter 2026 Earnings Summary

Financial Performance:

• Revenue for the three months ended September 30, 2026, was $0.1 million, compared to $0 in the same period in 2025.
• Cost of revenue (CVR expense) was $0.1 million in Q3 2026, compared to $0 in Q3 2025.
• Gross profit was $0.01 million in Q3 2026, compared to $0 in Q3 2025.
• Research and development expenses were $3.3 million in Q3 2026, a decrease from $14.5 million in Q3 2025.
• General and administrative expenses were $1.6 million in Q3 2026, an increase from $1.3 million in Q3 2025.
• Net loss attributable to common stockholders was $4.9 million ($0.14 per share) in Q3 2026, compared to $15.7 million ($8.20 per share) in Q3 2025.
• Cash and cash equivalents were $4.9 million as of September 30, 2026, down from $6.5 million as of December 31, 2025.
• Total assets were $75.6 million as of September 30, 2026, compared to $90.2 million as of December 31, 2025.
• Total liabilities were $11.5 million as of September 30, 2026, compared to $15.3 million as of December 31, 2025.
• Total stockholders' equity was $64.1 million as of September 30, 2026, compared to $74.9 million as of December 31, 2025.

Guidance and Future Outlook:

• Top-line results for the completed Halneuron® Phase 2b CINP study are expected to be announced in November 2026.
• The Phase 2b long-term extension study is expected to be completed in early 2027.
• Cash on hand of $4.9 million combined with the $5 million private placement provides an operational runway through the first quarter of 2027.

Business Segments and Product Lines:

• The Company completed the Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy (CINP), enrolling 239 patients.
• The Phase 2b long-term extension study is fully recruited with 95 patients enrolled to assess pain reduction over three months of treatment.
• The Company received and recognized $0.1 million in licensing revenue under the PRIDCor License Agreement.
• Halneuron® has received Fast Track designation from the FDA for the treatment of CINP.
• SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

Other Key Points:

• The Company closed a $5 million private placement with Sealbond Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., to advance Phase 3 preparatory activities and for working capital.
• Sealbond Limited is the Company's largest shareholder.
• Dogwood Therapeutics is a development-stage biopharmaceutical company with two first-in-class candidates: Halneuron® and SP16 IV.
• The Company has no FDA-approved medicines currently on the market.